The Committee for Medicinal Products for Human Use (CHMP) has recommended granting a conditional marketing authorization for Autolus GmbH’s Aucatzyl (obecabtagene autoleucel) in the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (B-cell ALL). B-cell ALL is a type of cancer affecting the white blood cells. Autolus GmbH’s medicine was supported through the European Medicines Agency’s PRIority MEdicines (PRIME) scheme, offering early and comprehensive scientific and regulatory backing for promising treatments addressing unmet medical needs.
Read more from thepharmaletter.com
